Business Description
Niki BioSolutions Inc
NAICS : 325411
SIC : 2834
ISIN : KYG6096M1226
Share Class Description:
NIKI: Class ATotal Employee Number:
1Description
Niki BioSolutions Inc, formerly Aptorum Group Ltd is a clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Aptorum's project pipeline includes SACT-1, a repurposed drug for the treatment of neuroblastoma, and ALS-4, a small molecule for the treatment of bacterial infections caused by Staphylococcus aureus, including but not limited to Methicillin-resistant Staphylococcus aureus (MRSA).
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1 | |||||
Equity-to-Asset | 1.24 | |||||
Debt-to-Equity | 0.15 | |||||
Debt-to-EBITDA | -2.43 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 61.6 | |||||
3-Year EPS without NRI Growth Rate | 60.5 | |||||
3-Year FCF Growth Rate | 58.5 | |||||
3-Year Book Growth Rate | -13.5 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 76.85 | |||||
9-Day RSI | 68.31 | |||||
14-Day RSI | 61.7 | |||||
3-1 Month Momentum % | -6.51 | |||||
6-1 Month Momentum % | -15.09 | |||||
12-1 Month Momentum % | -52.45 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.78 | |||||
Quick Ratio | 0.78 | |||||
Cash Ratio | 0.75 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -31.6 | |||||
Shareholder Yield % | -73.87 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -4.1 | |||||
ROA % | -5.23 | |||||
ROIC % | -8 | |||||
3-Year ROIIC % | -971.28 | |||||
ROCE % | -10.08 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 3 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 0.68 | |||||
PB Ratio | 0.34 | |||||
Price-to-Tangible-Book | 0.34 | |||||
EV-to-EBIT | 1.14 | |||||
EV-to-EBITDA | 1.14 | |||||
EV-to-Forward-Revenue | 0.5 | |||||
EV-to-FCF | 0.88 | |||||
Price-to-GF-Value | 0.82 | |||||
| Price-to-Net-Current-Asset-Value | 0.96 | |||||
| Price-to-Net-Cash | 0.98 | |||||
Earnings Yield (Greenblatt) % | 87.72 | |||||
FCF Yield % | -23.64 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:NIKI
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Niki BioSolutions Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.3 | ||
| Beta | -2.2016 | ||
| 3-Year Sharpe Ratio | 0.48 | ||
| 3-Year Sortino Ratio | 2.22 | ||
| Volatility % | 95.28 | ||
| 14-Day RSI | 61.7 | ||
| 14-Day ATR ($) | 1.246304 | ||
| 20-Day SMA ($) | 7.97065 | ||
| 12-1 Month Momentum % | -52.45 | ||
| 52-Week Range ($) | 6 - 44.7 | ||
| Shares Outstanding (Mil) | 0.81 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Niki BioSolutions Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Niki BioSolutions Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2026 | 2026-08-07 | In 16 days | ||
| 0.1:1 Stock Split | 2026-07-20 | 7.00 (-0.09%) | ||
| Annual report for 2025 | 2026-03-27 | 10.20 (-2.86%) | ||
| General meeting for 2025 | 2026-03-10 21:00 | 8.00 (+5.07%) | ||
| Annual report for 2024 | 2025-04-30 | 9.60 (+1.04%) | ||
| General meeting for 2024 | 2024-12-20 21:00 | 7.39 (+4.12%) | ||
| Second quarter earnings results for 2024 | 2024-12-20 | 7.39 (+4.12%) | ||
| 0.1:1 Stock Split | 2023-01-23 | 56.00 (+1.82%) |
Show
Entries
Niki BioSolutions Inc Frequently Asked Questions
What is Niki BioSolutions Inc(NIKI)'s stock price today?
The current price of NIKI is $9.54. The 52 week high of NIKI is $44.70 and 52 week low is $6.00.
When is next earnings date of Niki BioSolutions Inc(NIKI)?
The next earnings date of Niki BioSolutions Inc(NIKI) is 2026-08-07 Est..
Does Niki BioSolutions Inc(NIKI) pay dividends? If so, how much?
Niki BioSolutions Inc(NIKI) does not pay dividend.
Guru Commentaries on NAS:NIKI
No articles.
Press Release
Articles on Niki BioSolutions Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers